Equillium Inc (EQ) Stock Price, Quote & News

Company Profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 240 1200

Website: www.equilliumbio.com

Address:

2223 Avenida De La Playa, Suite 105, La Jolla, United States

BanditQ Oct. 24 at 3:06 PM

$EQ only biotech folk know about this gem

0 · Reply

BanditQ Oct. 20 at 12:17 PM

$EQ $25

0 · Reply

YanstersParadise Oct. 18 at 11:29 PM

$SPRB $TGL $EQ $COSM Crypto Treasury 💎👌🚀🚀🚀

0 · Reply

StockScanners Oct. 18 at 3:10 PM

$EQ keep watch if this holds above 1.24

0 · Reply

Dansaidso Oct. 17 at 6:17 PM

$EQ Have fun.

0 · Reply

Jakcofalltrades Oct. 14 at 3:34 PM

$EQ will be the same play as $ABVX

0 · Reply

BanditQ Oct. 13 at 2:01 PM

$EQ FAAAAAAK FAAAAAAK FAAAAAAAAAK

0 · Reply

SPYmyQQQ Oct. 13 at 10:03 AM

🚀 New Signal ✅ 💊 $EQ 🗓️ Oct 13, 2025 💵 Entry: $1.34 🎯 Target (Opt.): $1.59 (+18.84%) 👉 FREE TRIAL! Check bio.

1 · Reply

ErikTon Oct. 13 at 8:42 AM

$EQ what happened here?

0 · Reply

BanditQ Oct. 11 at 9:04 PM

$EQ hold till 2027

0 · Reply

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Oct 6, 2025, 4:02 PM EDT - 18 days ago

Equillium Announces Leadership and Corporate Updates

Sep 23, 2025, 5:30 AM EDT - 4 weeks ago

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Sep 3, 2025, 4:05 PM EDT - 7 weeks ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 29, 2025, 4:03 PM EDT - 2 months ago

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Aug 28, 2025, 5:35 PM EDT - 2 months ago

Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC

Aug 11, 2025, 8:30 AM EDT - 2 months ago

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Aug 4, 2025, 8:30 AM EDT - 2 months ago

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

May 6, 2025, 8:00 AM EDT - 6 months ago

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 1, 2025, 8:00 AM EDT - 6 months ago

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Apr 24, 2025, 9:00 AM EDT - 6 months ago

Equillium Announces Feedback from the U.S. Food and Drug Administration

Mar 27, 2025, 11:16 AM EDT - 7 months ago

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Mar 27, 2025, 7:00 AM EDT - 7 months ago

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Mar 27, 2025, 7:00 AM EDT - 7 months ago

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Feb 6, 2025, 8:00 AM EST - 9 months ago

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Nov 13, 2024, 4:01 PM EST - 1 year ago

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Nov 13, 2024, 8:00 AM EST - 1 year ago

Equillium to Present at the Stifel Healthcare Conference

Nov 12, 2024, 8:00 AM EST - 1 year ago

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Jul 18, 2024, 1:57 PM EDT - 1 year ago

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Equillium to Participate in Upcoming Investor Conferences

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Equillium to be included in the Russell Microcap® Index

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

May 29, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 9, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Dec 21, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Nov 13, 2023, 9:00 AM EST - 2 years ago

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Nov 8, 2023, 4:01 PM EST - 2 years ago

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 6, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Equillium to Host Analyst & Investor Day

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Sep 20, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Aug 9, 2023, 4:01 PM EDT - 2 years ago

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Equillium Announces $7.5 Million Share Repurchase Program

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

May 12, 2023, 4:15 PM EDT - 2 years ago

Equillium: A Negative EV Biotech With Compelling Programs And Cash 'Til At Least 2025; Worth A Look

BanditQ Oct. 24 at 3:06 PM

$EQ only biotech folk know about this gem

0 · Reply

BanditQ Oct. 20 at 12:17 PM

$EQ $25

0 · Reply

YanstersParadise Oct. 18 at 11:29 PM

$SPRB $TGL $EQ $COSM Crypto Treasury 💎👌🚀🚀🚀

0 · Reply

StockScanners Oct. 18 at 3:10 PM

$EQ keep watch if this holds above 1.24

0 · Reply

Dansaidso Oct. 17 at 6:17 PM

$EQ Have fun.

0 · Reply

Jakcofalltrades Oct. 14 at 3:34 PM

$EQ will be the same play as $ABVX

0 · Reply

BanditQ Oct. 13 at 2:01 PM

$EQ FAAAAAAK FAAAAAAK FAAAAAAAAAK

0 · Reply

SPYmyQQQ Oct. 13 at 10:03 AM

🚀 New Signal ✅ 💊 $EQ 🗓️ Oct 13, 2025 💵 Entry: $1.34 🎯 Target (Opt.): $1.59 (+18.84%) 👉 FREE TRIAL! Check bio.

1 · Reply

ErikTon Oct. 13 at 8:42 AM

$EQ what happened here?

0 · Reply

BanditQ Oct. 11 at 9:04 PM

$EQ hold till 2027

0 · Reply

uieriwer Oct. 9 at 10:26 AM

$EQ She's stuck in the mud

0 · Reply

BanditQ Oct. 8 at 11:46 AM

$EQ

0 · Reply

Aktienlord69 Oct. 8 at 9:34 AM

$EQ is martin still bullish on this?

1 · Reply

Moneyrollmoney Oct. 7 at 1:59 PM

$SOPA $ATCH $ASST $EQ I don't know magic. I only trade it with algorithm to get the higher probability of momentum stock to trade. Thank you for supporting Momentum. Join me for more daily momentum stock to trade. Follow me , follow momentum.

0 · Reply

BanditQ Oct. 7 at 10:51 AM

$SPRB if you missed it, try $EQ WILL 10x !!!

1 · Reply

The_Birdie_Gambit Oct. 7 at 7:47 AM

$EQ looking to start a position here. If Martin S likes it then I like it. I trust his analysis.

0 · Reply

BanditQ Oct. 6 at 11:34 PM

$SPRB $EQ is next $10+! You heard it here first

0 · Reply

sokrodney Oct. 2 at 11:27 PM

$EQ I think this might be the one! It found some support already around this level.. lets see 👀

0 · Reply

elmono Oct. 2 at 3:41 PM

$KZIA well that’s why you slowly buy into a position of size…this company will rerate after SABCS and a smart raise. I suggest a 100 million placement at around 9 will do the trick….in a month or so. $EQ or $PALI style…it’ll happen

1 · Reply

BanditQ Oct. 2 at 11:52 AM

$EQ

0 · Reply

elmono Oct. 1 at 1:49 PM

$PALI surprised not up 200-300% yet. News is beyond stellar 🤷‍♂️…guess we will wait as it will happen $EQ style x10 😂😂😂

0 · Reply

Smellmahass Sep. 29 at 9:49 PM

$EQ When are they releasing pivotal data? Martin S likes this.

0 · Reply

Market Cap	79.14M
Revenue (ttm)	41.10M
Net Income (ttm)	-8.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-19.64%
Debt to Equity Ratio	0.00

Volume	176,700
Avg Vol	1,664,448
Day's Range	N/A - N/A
Shares Out	59.50M
Stochastic %K	63%
Beta	1.53
Analysts	Sell
Price Target	$2.50